504538914
`
`09/08/2017
`
`PATENT ASSIGNMENT COVER SHEET
`
`EPASID: PAT4585621
`
`Electronic Version v1.1
`Stylesheet Version v1.2
`
`SUBMISSION TYPE:
`
`NEW ASSIGNMENT
`
`NATURE OF CONVEYANCE:
`
`ASSIGNMENT
`
`CONVEYING PARTY DATA
`
`ALLERGAN, INC.
`
`RECEIVING PARTY DATA
`
`Street Address:
`
`412 STATE ROUTE 37
`
`SAINT REGIS MOHAWK TRIBE
`
`City:
`
`State/Country:
`Postal Code:
`
`AKWESASNE
`
`NEW YORK
`13655
`
`Execution Date
`
`09/08/2017
`
`
`
`PROPERTY NUMBERS Total: 6
`
`Property Type
`Patent Number:
`
`Patent Number:
`
`8629111
`
`8633162
`
`Number
`
`
`
`8642556
`Patent Number:
`
`Patent Number:
`8648048
`
`Patent Number:
`
`Patent Number:
`
`8685930
`
`9248191
`
`CORRESPONDENCE DATA
`
`(714)246-4249
`Fax Number:
`Correspondencewill be sent to the e-mail addressfirst; if that is unsuccessful, it will be sent
`using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
`Phone:
`714-246-4500
`
`Email:
`Correspondent Name:
`AddressLine 1:
`AddressLine 4:
`
`patents_ip@allergan.com
`ALLERGAN, INC.
`2525 DUPONTDRIVE, T2-7H
`IRVINE, CALIFORNIA 92612-1599
`
`ATTORNEY DOCKET NUMBER:
`
`17618
`
`NAME OF SUBMITTER:
`
`SIGNATURE:
`
`DATESIGNED:
`
`Total Attachments: 6
`
`LAURA L. WINE
`
`/Laura L. Wine/
`
`09/08/2017
`
`504538914
`
`PATENT
`REEL: 043532 FRAME: 0422
`
`SRMT 2103 - Pg. 1
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`SRMT 2103 - Pg. 1
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`

`

`source=Short form-Patent Assignment - Signed#page 1 .tif
`source=Short form-Patent Assignment - Signed#page2.tif
`source=Short form-Patent Assignment - Signed#page3.tif
`source=Short form-Patent Assignment - Signed#page4.tif
`source=Short form-Patent Assignment - Signed#page5.tif
`
`source=Short form-Patent Assignment - Signed#pageé.tif
`
`PATENT
`REEL: 043532 FRAME: 0423
`
`SRMT2103 - Pg. 2
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`SRMT 2103 - Pg. 2
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`

`

`EXECUTION VERSION
`
`SHORT FORM PATENT ASSIGNMENT
`
`This Psteat Assignment (his “Assigament’} is made as of September §, 2017
`iguch dats, ihe “EWective Date"), by and hetween Allergan, Inc., ¢ Delaware corporation
`(‘Assignar’), and Seint Regis Mohawk Tribe, a foderally-recognized soversign Native
`American Tribe SAssigned™),
`
`WHEREAS, Astigner owns the patents and patent applications set forth im
`Attachment A (the “Patents}
`
`transfer, convey oud deliver
`WHEREAS, Assigner desires to assign,
`Assignes, aud Assignes wishes io scouire from Assigner, ali ofits right, ide end interest im, io
`and under dhe Patents; and
`
`WHEREAS, pursuant to, and updothe torres, obligations and conditions of, the
`Patent Assignment Agreement dated ae of September 8, 2017 (the “Long Form Agreement”),
`by and betwaen Assignor and Assignes, Assignordesires to confirm and perfect ite aseigament,
`transfer, conveyance and delivery to Assignee of all ofits right, Utle end interest in, to and
`under the Patents and in, to and under the inventions represemied thereby, and Assignee is
`desirous of confinning aad perfecting the same.
`
`NOW, THEREFORE, for good and valuable consideration, the receipt and
`sufficiency of which are hereby acknowledged, the parties herein, intending to be legally
`bourd, hereby agree sa follows:
`
`i. Assignment. Ae of the Effective Dete, Assigaer hereby conveys, transfers, assigns
`ami delivers to Assignee, gud Assignee hereby accepts the from Assignor, all of
`Assignor’s ight, title aad interest in, to and under the Patents, together with any
`relgsuas, reexamination, divisions, sostimationa, comfinuahons-in-part, extensions, and
`renewals of such Assigned Patents alrenedy granted and which may be granted thereon.
`The assigument contemplated herein ie meant to bean absolute assignment ard aot by
`way of security.
`
`
`be + Aggurances. As may be necessary, Agsignor shall execute, acknowledge and
`
`ver such other instruments, daciments and agreements and shall do auch other
`things as may he reasonably necesacy, proper or advizahie in carry out He obligations
`under thig Agreement and ag may be ressonably necessary, proper or advisable t more
`completely effectuate, consummate,
`record, perfect or confirm the transactions
`canvleniplated hereby.
`
`3. Becordation, The Assignor hereby authorizes the Director of Patents and Trademarks
`in the United States Patent and Trademark Office to recond Assignee as the assignee
`and owner of the Assigned Patents and to deliver to Assignee, and to Assignse’s
`atkwwsieya, agents, guocessors or assigns, all official documents and comeumications ae
`ray be warranted by tis Assignment, including bul sot limited io issuing any and all
`Letters Patents of the United Sines on inventions claimed in the Patents.
`
`
`4, No Other WarnersofSovercianlmmmmity. Assignee represents thai it has not and will
`
`net waive Hs saversign immumity or the sovereign immmnity af eny company,
`eomporation, enterprise, authority, division, subdivision, branch or other agency,
`instrumentality or clher government component of Assignee (each of the foregoing,
`
`Al ot
`*
` ge
`aware Lo
`=
`BA
`Gee & _
`8
`& # PAT NT
`REEL* 043532‘FRAME: 0424
`
`SRMT 2103 - Pg. 3
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`SRMT 2103 - Pg. 3
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`

`

`any inter partes
`including Assignee, a “Fribal Party"), in cack cage, in mletion
`review or any other priceeding in the Deited Suites Patent & Trademark Ciifice or any
`administrative proceeding that may be filed for the purpase ofinvalidating or rendering
`unenforceable any Assigned Patents. For parpdses of tis Assignment Agreement, no
`provision of this Assignment Agrosmant should be interpreted ip constitute a waiver of
`Assignes’s or any other Tribal Party's sovereign immunity ae te any inter pertes review
`or similar proceedings.
`
`GenerelProvisions, Assigner and Assignee each acknowledge and agree thet the
`representations, warranties, covermis, obligations and other terms contained in the
`Long Form Agreement shall not be superseded hereby, but shall remain in full force
`and effect te the ull extent provided therein. To the extent that any provision of this
`Agsignmont is inconsistent or conflicts with the Long Form Agreement, the provisions
`af the Long Form Agreement shall control. The parties nvey execute this Assignment
`inmaltple counterparts, any one of which seed aot contain the signature of more than
`one party, but all such countesparts ixken together shall constitute one and the sane
`instrament. Any counterpart may be oxecuted by facsinile or PDF signature and such
`facsimile or PIP signature shall be deemed anoriginal. The terms and cenditions of
`ihis Assignment shall be binding upon the parties hereto and their reepective successors
`and awigas. This Assignment shall be governad by and conetrued im acconlance with
`the laws ofthe Sate of New York, without giving effect fo the principles of conflines
`of law thereof.
`
`[Signatures Appear On The Following Pagel
`
` =
`
`BATENT
`
`REELLGAZO3/FRAME: 0425
`
`3¢.
`
`SRMT 2103 - Pg. 4
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`SRMT 2103 - Pg. 4
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`

`

`IN WITNESS THEREGE, Assignor and Assignes have caused their respective duly
`authorized officers io execute this Assignment ag of the Effective Date.
`
`Adergaa, hae. ae a
`
`Byfdaly
`x
`Name: A. Rober B. Bailey
`
`Tithe: President
`
`Name: Erte Thompsen
`
`Tide: Tribal Chief
`hohe break
`‘ot ASF ‘oe soon
`j
`/
`Nate: Beverly Cook
`
`By:
`
`Title: Tribal Chief
`
`Ap
`By: LbOABaherone
`
`Name: Michael Conners
`
`Tite: Tribal Chief
`
`Hgnatee Page tg Short Porn Patent Assignment dgreoment,
`«t
`
`PA
`REEE:"043532
`
`
`
`
`
`SRMT 2103 - Pg. 5
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`SRMT 2103 - Pg. 5
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`

`

`Aflachnent A — Phe Patents
`
`
`
`
`
`Z| 9-Nov-1999
`
`OG/008,924
`12-Nov-2002 |
`LOADS B29
`
`|fastaw2014|13/967,163
`
`
`
`
`‘Zdam-2014 | 13/967,179
`
`
`
`
`8,642,556
`4RebIGL | 15/967,189
`1 L-Feb-2014 |
`13/987,168
`
`
`
`
`8,648,048
`
`
`
`
`R.083930 Gb-Apedon| TVG BIS
`
`
`
`
`
`SAARISL|O2-Reb-RG | 14/222,478
`
` SAG L835
`
`
`
` - PMOSLBIS|OF-Auge2013- “Abandoned
`
`
`
`
`1/981,SOSoe | GT.Aug2013
`Abandoned
`
`
`
` BESO64
`
`
`
`
`=)elanRN|_Abandoned
`| SMay2017[Pending
`
`
`13-Sep-2003
`
`
`Abandoned
`L998,505
`
`
`15'806,612 aashpal-2009
`Abandoned
`i
`
`
`
`
`
`
`“TS-Now2004
`_TASL DBS
`TSS
`
`Mhfan-2006
`1879,481
`
`
`
`ihShabAS
`
`
`
`LH/TBE S09
`
`
`
`11/917.448
`
`
`eonbaidoned/
`
`
`
`
` ‘iat,
`
`
`
` |
`
`REE 0435 2 FRAME: 0427
`
`SRMT 2103 - Pg. 6
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`
`Aa822.
`
` defab2012T
`
`
`SRMT 2103 - Pg. 6
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`

`

`| Cousray
`
`2
`
`8,906,861
`
`
`
`“
`
`
` } 20-Nov-2007 \
`11/040,652
`i $Now2013 |
`
`
`
`3-Mar-2013 |
`16AY7L S27
`
`
`
`
` IVIBL AZ [| 13-Jel-2005
`
`84
`| 28-Feb-2007
`|
`Bennnvnnnns
`O06
`|
`13-Sep-2013
`|
`1
`
`
` 7,501,383
`
`
`
`
`is-Ange?uF
`
`1066,770
`
`
`13/966,849
`I4-Ang-2019
`
`
`
`14-Aug-2013
`
`
`Abandoned
`Abandoned
`
`
`Abandoned
`
`
`
`ESOL
`14-Oct-2008
`
`
`
`7,357,082
`US
`i
`|-Mar-2007
`
`
`
`
`
`i 8,207,129|26hunUS VR407.886|
`mnneneedbennenneeennnnnenentenneetenenesensGeenatanenencnnsencnnennanentnnnn Bataan
`
`GNTIS120 |
`Sebviar-2006
`
`
`aenenntninnrnennvere
`eCeee
`856178
`PRebQ0L?|1i/781,095
`
` 22-Feb-2008
`
`
`
`&Febi0) 7
`
`Abandoned
`Pending
`Lapsed Provisional
`
`
`
`,
`
`
`
`Abandoned
`
`SRMT2103- Pg. 7
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`SRMT 2103 - Pg. 7
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`

`

` Toned_
`
`Pending
`bendoned~~
`
`‘Abandoned
`
`Abandoned
`
`Pending
`
`
`
`Attachment 4 io Short Form Patent Assignment dgroement
`
`RECORDED: 09/08/2017
`
` eran4,Kex
`
`REEL: 043532 FRAME:¢0429
`
`SRMT 2103 - Pg. 8
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`SRMT 2103 - Pg. 8
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01130
`
`